A Dose Escalation Study of Sorafenib (BAY 43-9006, NSC 724772) in Nomotensive Patients With Advanced Malignancies.
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2013
At a glance
- Drugs Sorafenib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- 01 Jul 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 14 Jan 2013 Planned End Date changed from 1 Sep 2007 to 1 Sep 2011 as reported by ClinicalTrials.gov.
- 14 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.